Assessment of harms, benefits, and cost-effectiveness of prostate cancer screening: A micro-simulation study of 230 scenarios.
Abraham M GetanehEveline A M HeijnsdijkMonique J RoobolHarry de KoningPublished in: Cancer medicine (2020)
PSA screening beyond age 64 is not cost-effective and associated with a higher risk of overdiagnosis. Similarly, starting screening before age 55 is not a favored strategy based on our cost-effectiveness analysis.